Crossmark

Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets

Crossref DOI link: https://doi.org/10.1186/s13099-024-00637-5

Published Online: 2024-08-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Oh, Han Na

Shin, Seung Yong

Kim, Jong-Hwa

Baek, Jihye

Kim, Hyo Jong

Lee, Kang-Moon

Park, Soo Jung

Kim, Seok-Young

Choi, Hyung-Kyoon

Kim, Wonyong

Sul, Woo Jun

Choi, Chang Hwan
Funding

Funding for this research was provided by:

AbbVie and the National Research Foundation of Korea (NRF-2017R1D1A1B03031924)
License Information

Text and Data Mining valid from 2024-08-26

Version of Record valid from 2024-08-26
More Information

Article History

Received: 15 February 2024

Accepted: 16 August 2024

First Online: 26 August 2024

Declarations

:

: This manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal. This study was performed in accordance with the principles of the Declaration of Helsinki and approved by the Institutional Review Board of Chung-Ang University Hospital (IRB No. C2015020). Written informed consent was obtained from each participant before inclusion into the study.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below